AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET

Conclusions

BCG022 is a novel and fully human bispecific antibody-drug conjugate generated from the RenLite® platform that exhibits cross-species reactivity to human and cynomolgus monkey HER3 and MET.
BCG022 candidates can bind a wide range of HER3/MET co-expressing cancer cell lines, including NSCLC, gastric, liver, colorectal and pancreatic cancers.
BCG022 demonstrated higher endocytosis in HER3/MET co-expressing tumor cells than parental HER3 monoclonal ADCs, and stronger tumor growth inhibition than parental ADCs.
BCG022 showed strong anti-tumor efficacy in both CDX and PDX models.

Please fill out the form below to request a download of this poster

First Name *

Last Name *

Company/ Institution*

Work Email *

Country *

State/ Province *

How did you hear about us? *